The foundations of pharmaceutical biotechnology mainly lie in the capability of plants, microorganism and animals to produce low and high molecular weight compounds useful as therapeutics. Although molecules from plants and microorganisms are preferred extraction from plant biomass needs tedious downstream processing while in case of microorganisms it is easy with fewer amounts of impurities. Pharmaceutical biotechnology is poised to flourish for the last 4-6 decades with the advent of recombinant DNA technology and metabolic engineering supported by the well-developed bioprocess technology. Large scale production and cost effectiveness and affordability could be achieved by way of synergising all these technologies. In the current review importance of microorganism in conjunction with recombinant DNA technology is discussed for the production of biopharmaceuticals and development of therapeutic applications using recently developed molecular methods and mechanisms of disease progression. Bacterial enzymes are being used in applications from drug modification to therapeutic uses.

Keywords

Pharmaceutical biotechnology; DNA technology; Bioprocess technology; Biopharmaceuticals

Introduction

Plant and microbial products, in form of natural preservatives have been known since centuries for preservation of fruits, vegetables and milk in the form of bread, yoghurt, beer, wine, vinegar, cheese, pickles and other fermented materials. After the accidental discovery of the antibiotic molecule penicillin in 1929 by Alexander Fleming, the economic importance of microorganisms gained importance and bioprocesses such as fermentation, bioconversion and enzymatic biotransformation for production of various valuable products from microorganisms were explored [1]. These products included antibiotics, amino acids, enzymes, enzyme inhibitors, nucleotides, vitamins, organic acids, vaccines and polysaccharides with applications in the field of medicine to improve human health. Plants and microorganisms, particularly bacteria, fungi, yeast and microalgae are a vast resource of biopharmaceuticals and could be produced using fermentation process or direct extraction from plant biomass. Secondary metabolites from microorganisms are reported to be important for pharmaceutical applications. Secondary metabolism consists of synthesis of special metabolites possessing unusual chemical structures and is not critical for the growth and development of producing organisms. Secondary metabolites initiation and biosynthesis are possibly due to the deficiency of nutritional growth limiting components. Actinomycetes, mycobacteria, eubacteria, algae, fungi are reported to produce a large repertoire of bioactive showing therapeutic properties. In the last 4-5 decades much attention has been paid for isolation and characterisation of pharmaceuticals from endosymbiotic microorganisms that thrive in plant tissues, sponges and animals. Marine ecosystem has been credited as a source of microorganisms that produce inexhaustible and valuable molecules for application as pharmaceuticals. The areas are even expanding using the knowledge of microbiology, recombinant DNA technology, metabolic engineering combined with synthetic chemical technology (Scheme 1). Even, some complex biomolecules could be synthesised using chemical methods; however, they suffer with inherent drawbacks such as purity, containing isomeric forms and product purification.

Scheme 1 Overview of Pharmaceutical Biotechnology.

Microorganisms have unique characteristics which make them irreplaceable, industry friendly hosts, as they are the real workhorses for large scale production of an array of useful metabolites. Microorganisms have a high ratio of surface area to volume, which facilitates the rapid uptake of nutrients required to support high rates of metabolism and biosynthesis suitable for variety of reactions (Table 1). The microorganisms can be isolated from various ecological niches allowing them to be transplanted from nature to the laboratory flask and ultimately to the production scale fermenter, where it is capable of growing on inexpensive carbon and nitrogen sources and producing valuable compounds. With the development of recombinant DNA technology, microorganisms could be manipulated genetically with ease, to increase production of the products. Although microbes are awfully superior in presenting us with an astonishing array of valuable products, they usually produce them only in small amounts. To overcome this bottleneck, in early 1970s traditional industrial microbiology in combination with molecular biology, tailor made microbial strains have been developed for large scale production. The modern biotechnology industry has made a major impact in the business world; the biopharmaceuticals (recombinant protein drugs, vaccines and monoclonal antibodies) have a market of around 15 billion dollars. As a result of technological improvements in screening programs, separation and product purification techniques, the number of natural compounds discovered so far is estimated to be more than one million. From the 22500 biologically active compounds that have been obtained so far from microbes, 45% are produced by Actinomycetes, 38% by fungi and 17% by unicellular bacteria, it is obvious that most microbial products are made by fermentation technology. Despite the efficiency of the chemical route to riboflavin synthesis, much of the production of this compound is carried out currently by fermentation. Most natural products are so complex and contain so many centres of asymmetry that they probably will never be made commercially by chemical synthesis [2,3]. Several biopharmaceuticals are produced using recombinant DNA technology as they are safer and are effective than conventionally produced molecules and also to make them cost-effective. For instance insulin was proved effective and safer in comparison to the insulin obtained from animal sources. The biopharmaceuticals obtained through recombinant DNA technology include recombinant insulin, interferon’s, hepatitis B vaccine, somototrophin, etc., A large number of biopharmaceuticals are produced and marketed by biotechnology companies which come under one of the below mentioned categories.

S. No. 1 Cytokines Interferons (α-2a, β-2a) Interleukins (Interleukin-2) Granulocyte colony stimulating factor (G-CSF) Granulocyte macrophage stimulating factor (G-CSF) 2 Enzymes Altephase (Plasminogen activator) Dornase α (Pulmozyme for cystic fibrosis) Imiglucerase (for treatment of Gaucher’s disease) 3 Hormones Lispro Epotein alfa (for treatment of anemia) Recombinant human growth hormone 4 Clotting factors Antihemophilic factor (for treatment of hemophilia) Factor IX (for treatment of hemophila B) 5 Vaccines Hepatitis B Ebola Cholera 6 Monoclonal antibodies MoAb muromonab-CD3 (treatment of immune system rejection) MoAb Infliximab cA2 (treatment of Crohn’s Disease) 7 Enzyme inhibitors Clavulinic acid Ancovenin Streptovaricin Streptonigrin Lovastatin Monacolin K 8 Immunosuppressors Cyclosporin Rapamycin 9 Polyamino acids Epsilon poly-L-lsine Polyglutamic acid cyanophycin

Table 1 Some of the Biopharmaceutical categories.

Bacterial polysaccharides as pharmaceuticals

Microbial exopolysaccharides (EPS) are biopolymers synthesized by several microorganisms which include several genera of bacteria, molds and yeasts. These are gum like polymers synthesized by these organisms and released into the surrounding environment. EPS mainly protects the microorganisms from the surrounding environment and also acts as a reserve food material, and the producing organisms can use this as a main carbon source. Based on the sugar composition, EPS are classified as homopolymers (with a single type of sugar, glucose, or xylose,) and heteropolymers (with more than one type of sugar moieties, glucose, rhamnose, mannose, etc.,). Based on the presence or absence of uronic acid, EPS are categorized as acidic or neutral EPS, respectively. Some of these EPS can form a film, some form gels, some more can increase the viscosity of solutions. Due to their varied functional properties, microbial EPS found applications in various fields such as agriculture, cosmetics, food, oil recovery, packaging, textile, wastewater treatment, pharmaceuticals, medicine, and in the form of membranes. Several health benefits such as antitumor activity, anti-atherosclerotic effect, immunomodulation activity, and prebiotic effect of lactic acid bacteria and other microbial EPS are reviewed recently [4,5]. Antarctic bacterium Pseudoalteromonas sp. S-5 producing an EPS, showing anticancer activity, was recently reported [6]. Gellan finds a variety of applications as an ingredient of oral, ophthalmic, and nasal formulations, tissue engineering, and dressing material [7]. Applications of xanthan gum has been reviewed in drug delivery, due to its potential in retarding the drug release, in the form of liposomes, hydrogel, niosomes, nanoparticles, matrix system, or microspheres [8]. Recently, phosphorylated curdlan micro gels were prepared for in vitro drug release, and these micro gels were found to show excellent biocompatibility [9]. The production and applications of microbial celluloses in medical and pharmaceutical fields was reviewed [10]. Bacterial cellulose is considered to be a best alternative to wound dressing material due to its water-holding capacity, porosity, and efficient barrier properties as well as nanofiber material. Several investigations have been reported on application of bacterial cellulose as artificial skin or membrane or as wound dressing material over burn injuries. Some studies were carried out to use bacterial cellulose as excipient and as to use it as slow drug release material in the field of pharmaceutical biotechnology. The authors have carried out extensive research on the production of bacterial cellulose produced by Gluconacetobacter xylinus for various applications (Figure 1). Derivatization increased functionality of levan in terms of increased reducing power, scavenging activity, antioxidant, and anticancer activity [11]. At 0.1 to 1.0% concentrations, levan is an excellent immunostimulant in fishes [12]. Fructooligosaccharides derived from acid hydrolysis of levan are considered as prebiotic agents [13]. Levan has several medical applications such as an anticlotting factor in heart surgery, healing wounds, after angioplasty anti-AIDS agent, and in the subcutaneous dental filling [14].

Figure 1 Bacterial cellulose production by Gluconacetobacter xylinum.

Algal pharmaceuticals and therapeutics

Microalgae possess unique characteristics compared to conventional microorganisms, such as photosynthetic ability and massive species and bio product diversity. As such, algae are highly attractive candidates for application as cell factories. Macroalgal pigments also have demonstrated their lack of toxicity and biological activity in a wide range of biological applications, including prevention of acute and chronic coronary syndromes, atherosclerosis, rheumatoid arthritis, muscular dystrophy, cataract and neurological disorders. They are also recommended to protect the skin and eyes against UV radiation [15]. Lutein is one of the major xanthophylls found in green microalgae. It is accumulated in the macula of the human retina and elicits protection for the eyes from oxidative stress, and acts as a filter of the blue light preventing macular degeneration and age-related cataract [16-18]. Because of their antioxidant and anti-inflammatory activity, most microalga pigments have neuroprotective effects in cultured rat cerebellar neurons, and hepatoprotective effects in hepatocytes grown in vitro (e.g., phycocyanin, phycoerythrin). Antiviral and antifungal activities were noticed with allophycocyanin and phycocyanin [19]. In addition to the utilization of microalgal biomass rich in proteins and minerals for food and feed purposes, there are beneficial special compounds produced by these organisms, such as pigments, enzymes, sugars, lipids with valued fatty acids, sterols, and vitamins i.e., β-carotene, thiamine, riboflavin, niacin, pantothenic acid, pyridoxine, biotin, folic acid. Additionally, the generation of other scarce bioactive compounds, displaying immune mediation, anticancer, anti-inflammatory and antibiotic activity, is reported [20-22]. Algae can act as chemical platforms for cosmetic purposes (e.g., coloring pigments and especially anti-aging skin supplements. Extracts from Chlorella vulgaris are reported to support collagen repair in addition to pharmaceutical and therapeutic applications [23]. The exploitation of microalgae for special metabolites is highly attractive because these frequently display exceptionally high market values. Sulphated polysaccharides extracted from marine algae were found to be anti-oxidant, anti-coagulant, anti-inflammatory, anti-viral, antibacterial, anti-tumour, immunomodulatory and radio-protective.

Microalgae produce a variety of compounds for adaptation and survival at different environmental conditions. Many marine microalgal strains produce a high percentage of total lipids (up to 30-70% of dry weight) [24]. The accumulation of fatty acids is closely linked to microalgal growth stages, functioning as an energy stockpile during unfavourable conditions or cell division. Omega-3 fatty acids are accumulated due to its high energy content, as well as the good flow properties crucial for cellular functions [25,26]. To date, the ω-3 fatty acid content of numerous microalgae strains have been studied. Strains from the genera Phaeodactylum, Nannochloropsis, Thraustochytrium and Schizochytrium have demonstrated high accumulation of Eicosapentaenoic acid (EPA) and/or Decosahexaenoic acid (DHA). Phaeodactylum tricornutum and Nannochloropsis sp. demonstrated an EPA content of up to 39% of total fatty acids, whereas the strains such as Thraustochytrium and Schizochytrium limacinum contained a DHA percentage of 30–40% of total fatty acids. Omega-3 fatty acids represent an important structural component of human cell membranes, particularly neuronal cells [27-31]. The consumption of EPA and DHA supplements has been shown to prevent cardiovascular, nervous system and inflammatory diseases. Regular consumption of ω-3 fatty acids reduce the risk of hypertension, thrombosis, myocardial infarction and cardiac arrhythmias due to the increase in the high-density lipoprotein/low-density lipoprotein (HDL/LDL) ratio and decrease the total cholesterol/ HDL ratio [32]. In addition to cardiovascular benefits, omega-3 fatty acids have also demonstrated positive effects on brain function and the nervous system (Table 2). In pregnant women, the adequate intake of EPA and DHA is crucial for healthy development of the fetal brain [33,34]. In infants, arachidonic acid (ARA), an omega-6 fatty acid, and DHA were found to be essential for normal growth and functional development [35]. The increased consumption of DHA may also diminish the severity of depression [36]. Immunomodulatory effects have been observed when ω-3 fatty acids were used in the treatment of inflammatory conditions such as rheumatoid arthritis, Crohn’s disease, ulcerative colitis, psoriasis, asthma, lupus and cystic fibrosis [37-39]. There is currently a large demand for microalgae in the nutraceutical and pharmaceutical industry due to their health-promoting effects. Macroalgalderived PUFA, such as ARA and DHA are added as fortifications to infant formulae an industry that is worth $10 billion per year. To date, microalgal extracts can be found in many face and skin care products, e.g., anti-aging cream, refreshing or regenerative care products, sun cream, emollient and anti-irritant in peelers [40]. Dermochlorella is extracted from Chlorella vulgaris, which is known to stimulate collagen synthesis in skin supporting tissue regeneration and wrinkle reduction [41]. Protulines is a proteinrich extract from Arthrospira (Spirulina), which helps combat early skin aging, exerting a tightening effect and preventing wrinkle formation [42].

Bioactive Compound Source Pharmaceutical application Polyunsaturated fatty acids (PUFA) Eicosa pentenoic acid (EPA) Isochrysis galbana, Nannochloropsis oculata,

Nitzschia laevis,

Phaeodactylum cornutum,

Porphyridium cruentum,

Porphyridium purpureum, Phaeodactylum tricornutum Nutritional supplement, heart diseases, lowers blood pressure, lowering plasma levels of cholesterol and other lipids, anti-thrombosis and anti-arthrosclerosis. Docosa hexaenoic acid (DHA) Crypthecodinium cohnii,

Pavlova lutheri,

Schizochytrium limacinum,

Ulkania sp. Important for brain and eye development during fetus stage and

in children, adult dietary supplement to improve cardiovascular health and cancer prevention. Eicosatetraenoic acid (arachidonic acid, ARA) Porphyridiumsp. Nutritional supplement,

Anti-inflammatory, muscle anabolic formulations. Octadecatrienoic acid (γ-linolenic acid, GLA) Spiriulinasp. Nutritional supplement,

Anti-inflammatory useful to suppress tumor growth and metastasis. Pigments Marrenine Haslea ostrearia Anti-proliferative effect on

lung cancer model, antiviral and anticoagulant properties. Pyropheophytin a

fucoxanthin (Fuco) Brown macroalgae such as Eicenia bicyclis,

Hijikia fusiformis Hepatoprotective Phycoerythrin Brown macroalgae such as Eicenia bicyclis,

Hijikia fusiformis Hepatoprotective β-carotene Dunaliella salina,

Dunaliella bardawil, Botryococcus braunii Pro-vitamin A, antioxidant, food additive. Microcolins A and B Cyanaobacter Immuno suppresive activity Vitamin E Euglena gracilis Vitamin supplement. Lutein Green microalgae

Chlorella protothecoides, Chlorella zofingiensis, Botryococcus braunii,

Chlorococcum citriforme, Dunaliella salina, Muriellopsis sp., Neospongiococcum gelatinosum Treatment of age-related cataract, anti-macular degeneration, anti-colon cancer, cosmaceutical. Phycoerythrin Cyanobacteria, Porphyridium Immunofluorescent techniques, labelled antibodies, receptors

and other biological molecules. Phycocyanin Spirulina(Cyanobacteria) Cosmetics, immunofluorescent techniques, antibody label. Zeaxanthin Botryococcus braunii,

Dunaliella salina, Nannochloropsis oculata,

Nannochloropsis gladitana Anti-colon cancer, eye health. Astaxanthin Haematococcus pluvialis Anti-colon cancer, eye health. Amino acids Amino acids Diatom Dermatological applications and as cosmaceuticals. Mycosporine-like amino acids (MAAs) Microalgae Sunscreens to reduce UV-induced damage and as ROS scavengers. Vitamins α-Tocopherol Chlorella sp.,

Nannochloropsis oculata, Stichococcus bacillaris,

Euglena gracili. Vitamin E, food additive, antioxidant and cosmaceuticals. Polysaccharides Polysaccharides Red microalgae such as

Porphyridium sp., Antiviral activity. ß-1,3-glucan Chlorella Immune-stimulator, antioxidant and reduction of blood cholesterol Alginates, cellulose, or carrageenan Rhodophyta group Several pharmaceutical applications. Sulfated exopolysaccharide Cytotoxic effect towards human cancer cell lines

Table 2 Algal pharmaceuticals and therapeutics.

For deployment as oral vaccines, some algae are permitted and they have been certified as generally recognized as safe (GRAS) for human consumption by the Food and Drug Administration. In addition, algal vaccines offer a number of unique advantages over conventional plant therapeutics, such as rapid growth (relative to terrestrial plants), minimal environmental impact from lateral gene transfer, and minimal processing requirements [43]. Algal plastid production of fully active, monoclonal human antibodies was first reported in C. reinhardtii chloroplasts [44]. The RuBisCO large subunit (rbcL) and plastidial ATP synthase (atpA) promoters were utilized in conjunction with rbcL 50 and 30 UTR sequences for plasmid construction, generating a single-chain antibody targeting glycoprotein D of the herpes simplex virus. In another development, production of a chimeric protein composed of a mucosal adjuvant (CtxB) and a malaria transmission-blocking vaccine candidate (Pfs25) was demonstrated in C. reinhardtii [45]. Oral vaccination in mice was found to elicit both IgG and IgA antibodies’ production. Tran and colleagues recently built upon this work to express single chain antibodies targeting the B cell surface antigen CD22 fused to an immunotoxin. Fusion protein produced dimeric immunotoxins capable of binding and reducing B-cell lymphoma viability [46,47].

Microbes and their metabolites as drug and enzyme delivery systems

To achieve efficient and biocompatible targeted drug delivery, various technologies have been developed to deliver chemotherapeutic agents, antibiotics, therapeutic proteins, and biomolecules. One novel aspect could be the application of biofilm formation by drug-carrying bacteria to deliver drugs/ antibiotics to the site of infection. Biofilm formation in the human body via various commensals is very common. These commensal biofilms can be productively used to deliver various compounds such as drugs, enzymes, etc. [48]. A non-pathogenic commensal surviving in the human system as a biofilm can be further augmented with the population enriched with specific enzyme-secreting engineered bacteria. The same principle can be applied to eliminate biofilm via targeted delivery of alginate lyase or mucinase-overproducing bacterial strains (Table 3). A chimeric E. coli strain expressing the glucan digesting enzymes mutanase and dextranase, which decompose the Streptococcus mutans biofilm under in vitro conditions was recently designed by Otsuka [49]. Previous reports claim the treatment of murine colitis by implanting the engineered Lactococcus lactis -secreting interleukin-10 in mice colon [50]. Other E. coli engineered systems were used for gut inflammation [51]. In an identical study, the attenuated strains of Salmonella typhimurium are genetically modified to trigger the production of the tumour necrosis factor related apoptosis- inducing ligand (TRAIL) under a hypoxiainduced targeted promoter system nirB [52]. When administered, this strain specifically targeted the malignant melanoma of mice. Various bacteria invade tumours and have been engineered to destruct them by releasing a chemotherapeutic prodrug, via secretion of TNFα and cytokines [53-55]. However, a synthetic biological approach would allow designing a bacterium rationally with desired capabilities and safety requirements. The Voigt lab constructed an E. coli strain that senses a low-oxygen microenvironment such as found in tumour tissues. Hypoxia is the cue in this particular E. coli strain to upregulate a Yersinia pseudotuberculosis adhesin protein (invasin) sufficient for E. coli to invade mammalian cells. Because invasion is only efficient from a certain cell density, the Voigt lab further equipped this E. coli with a second sensor including another genetic circuit that senses cell density (quorum sensing circuit from Vibrio fischeri) [56]. Thus, this E. coli strain should specifically invade tumour cells in a population density-dependent manner. The authors have carried out research on the production of polyhydroxybutyrate (PHB) by B. mycoides which is useful for biomedical applications such as surgical threads, slow release of antibiotics, medical disposables and as scaffolds with slow drug release functions (Figures 2-4).

Figure 2 PHB granules after Nile Red staining in Bacillus mycoides.

Figure 3 Field Emission Scanning Electron Microscopy of PHB granules (10000X) after cell disintegration.

Figure 4 Purified PHB film.

Recombinant therapeutic proteins Source Pharmaceutical Application Artemisinin Recombinant E. coli Anti-malarial drug. Paclitaxel (Taxol) Recombinant E. coli Anti-cancer agent anti-neoplastic drug. Eleutherobin Recombinant E. coli Anti-cancer agent. Erythromycin and

Epothilone C and D Recombinant E. coli Anti-cancer drugs. Aromatic bacterial

polyketides Recombinant E. coli Precursor to several antitumor polyketides. Humulin Recombinant E. coli Diabetes. Protropin Recombinant E. coli hGH deficiency. Roferon A Recombinant E. coli Hairy cell leukemia Cancer, genital warts and hepatitis. Interferon alpha Human lymphoblastoid

cells AIDS-related Kaposi’s sarcoma, multiple myeloma, non-Hodgkin lymphoma. Interferon alpha-2a Recombinant E. coli Treatment of Kaposi’s sarcoma, follicular

lymphoma, cutaneous T-cell lymphoma, melanoma, chronic myelocytic leukemia,

kidney cancer. Interferon alpha-2b Recombinant E. coli Treatment for cancers, pancreatic melanoma,

non-Hodgkin lymphoma, leukemia, hairy cell leukaemia, renal cell carcinoma, multiple myeloma, follicular lymphoma. Interferon alpha-1b Recombinant E. coli Renal cell carcinoma, hairy cell leukemia. Interferon gamma-1a Recombinant E. coli Kidney cancer. Tasonermin Recombinant E. coli Natural Cytokine Soft tissue sarcoma Molgramostim Recombinant E. coli Myelo dysplastic syndrome Nartograstim Recombinant E. coli Solid tumour Filgrastin Recombinant E. coli Stimulates hematopoiesis and treatment for neuatropenia. Humatrope E. coli hGH deficiency Recombivax Recombinant Saccharomyces cerevisiae Hepatitis B Intron A Orthoclone OKT3 Hybridoma cell line Reversal of acute kidney and transplant rejection Denileukin diftitox E. coliFusion protein Cutaneous T-cell lymphoma Activase CHO cells Acute myocardial infarction Epogen CHO cells Anaemia Trastuzumab biosimilar CHO cells Breast and gastric cancer. Thyrotropin alpha CHO cells Thyroid cancer Darbepoetin α (Aranesp) CHO cells Red blood cell production. Epoetin α (Binocrit) CHO cells Stimulates production of RBCs. Hyaluronic acid/ Hyaluronan Bacillus subtilis Cell therapy, tissue engineering and regenerative medicine.

Table 3 Recombinant therapeutic proteins from microorganisms.

Recombinant therapeutic proteins from microorganisms

Since the production of recombinant insulin in the late 70s, the emergence of molecular biology and biotechnology has enabled the biological fabrication of a long list of active therapeutic proteins. Today, recombinant DNA and hybridoma cell technologies are mainstream platforms to obtain most of the currently marketed protein drugs such as monoclonal antibodies, hormones, cytokines and growth factors [57,58]. Over 200 protein drugs are expected to be available over the next few years to treat expanding human disorders such as diabetes, cancer, respiratory, cardiovascular and inflammationrelated diseases, as well as other rare diseases. In fact, the global market for protein drugs already exceeds US $50 billion, with an average annual growth rate of almost 4%, according to BCC Research. Unfortunately, the costs of protein drugs are often extremely high. As a representative example, recombinant human Erythropoietin (EPO), which is used as treatment for anaemia due to kidney failure or anticancer treatments costs over 2 billion US $ per kg, probably being the most expensive existing substance today. Enzyme replacement therapies such as for lysosomal storage diseases (LSD) representing excess of 0.15 million $ per year per patient. Such high costs are partially explained not only by the investment in product development but also by the expenses associated to quality analysis and control [59,60]. In addition, the immature state of the current production methods raises manufacturing costs to a level often unaffordable from an industrial point of view. With the exception of short peptides, suitable to be produced by chemical synthesis, protein pharmaceuticals have to be produced in living cells or transgenic organisms, poses important challenge to industriallyscaled production [61]. Manufacturing a recombinant protein or an antibody might represent up to 25% of the global sale figures, imposing a strong need to find cost-effective alternatives to the current recombinant fabrication systems [62,63]. Among the different steps of recombinant protein production, downstream processing might impose a load of up to 80% of the total process cost, a figure that can be slightly reduced by adapting the equipment, specially moving from steel bioreactors to disposable tanks [64,65]. Interestingly, the major factor influencing the process cost is the biological platform used as cell factory [66]. On the other hand, many protein drugs are often unstable during production and/or purification and tend to aggregate [67]. Systemic administration of protein drugs is especially sensitive to aggregation, which can also occur during storage or in a form of unnoticed soluble aggregates. Many side effects and undesired immunoreactions have been found to be linked to protein instability and aggregation in the body [68-70]. Improving protein solubility represents a continuous challenge in the development of protein drugs [71]. As a result, biopharmaceuticals still suffer from batch-to-batch conformational heterogeneity, a currently unavoidable disadvantage inherent to recombinant biological production. These drawbacks complicate the consideration of proteins as clinical drugs from the regulatory point of view. Moreover, proteins with therapeutic value often undergo posttranslational modifications necessary for the natural biological function.

Conclusion

Plants, animals and microorganisms have become dispensal source for the production of pharmaceuticals. Current, microbial sources, either wild strains are developed bu recombinant DNA technology, conventional mutagenesis or metabolic engineering, are mostly preferred for the production of biopharmaceuticals under various categories (Table 1). For the production of monoclonal antibodies or large number high value biopharmaceuticals and vaccines animal cell lines are being used in production scale fermenters to achieve costeffective and to address safety concerns. The biopharmaceutical technology is mammoth field including biopharmaceuticals to cure and prevent diseases such as cancer, cardiovascular problems and growth retardation in children, to treat viral, bacterial and mycotic infections. The repertoire of therapeutic molecules is further burgeoning using microorganisms, plants and animals from marine and fresh water sources. Further the endosymbiotic microorganisms from plants, sponges and animals have enhanced the prospects of finding a plethora of bioactive molecules. The overall, biopharmaceutical production platform includes microorganisms, animal cell lines, plants and animals. In the near future metabolic engineering and synthetic biology would further augment drug discovery and biopharmaceutical production to treat diseases effectively.

References